Journal of Neurology

, Volume 250, Supplement 3, pp iii44–iii46

Do patients with Parkinson’s disease benefit from embryonic dopamine cell transplantation?

  • Curt R. Freed
  • Maureen A. Leehey
  • Michael Zawada
  • Kimberly Bjugstad
  • Laetitia Thompson
  • Robert E. Breeze

Abstract.

Embryonic dopamine cell transplants survive in nearly all patients regardless of age and without immunosuppression. Transplants can improve Parkinson “off” symptoms up to the best effects of L-dopa observed preoperatively. They cannot improve the “best on” state. Transplants appear to survive indefinitely. In 10 to 15% of patients, transplants can reproduce the dyskinetic effects of L-dopa even after discontinuing all L-dopa. Neurotransplantation should be tried earlier in the clinical course of Parkinson’s to see if earlier intervention can prevent progression of the disease, particularly the dyskinetic responses seen after longterm L-dopa treatment.

Key words

putamen positron emission tomography (PET) fluorodopa embryonic stem cells double-blind neurosurgery 

Copyright information

© Steinkopff Verlag 2003

Authors and Affiliations

  • Curt R. Freed
    • 1
  • Maureen A. Leehey
    • 1
  • Michael Zawada
    • 1
  • Kimberly Bjugstad
    • 1
  • Laetitia Thompson
    • 1
  • Robert E. Breeze
    • 1
  1. 1.Departments of Medicine, Neurology, Psychiatry, and Neurosurgery BoxUniversity of Colorado School of MedicineDenverUSA

Personalised recommendations